Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury
Bupropion moderately decreases plasma levels of ADMA and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1.
Authors
- Chunhua Xia (ORCID: https://orcid.org/0000-0003-0675-149X)
- Yongjie Zhang (ORCID: https://orcid.org/0000-0002-1964-4258)
- Yun Xiao (ORCID: https://orcid.org/0000-0003-1779-7741)
- Yang Yu (ORCID: https://orcid.org/0000-0002-7605-5732)
- Lulu Huang (ORCID: https://orcid.org/0009-0007-5709-6874)
- Fanglan Liu (ORCID: https://orcid.org/0000-0002-5189-6658)
- Xiaoyu Han (ORCID: https://orcid.org/0000-0002-0855-0563)
- Li Q (ORCID: https://orcid.org/0000-0003-3060-3323)
- Jiake He (ORCID: https://orcid.org/0000-0002-0579-6189)
- Chao Zheng (ORCID: https://orcid.org/0000-0003-2075-0186)
- Xiangdong Fang (ORCID: https://orcid.org/0000-0002-6628-8620)
Institutions
- Nanchang University (CN)
- China Pharmaceutical University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Third Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3389/fphar.2025.1565713
- Citations
- 1
- Primary Topic
- Nitric Oxide and Endothelin Effects
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- National Natural Science Foundation of China